Home » Newsletters » BioWorld Science

BioWorld Science

May 17, 1999

View Archived Issues

Novel MSI delivery system tested in breakthrough pain therapy

Vitamin D analogue Ro-25-6760 is a promising treatment for colon cancer

Company Profile: Redox

Vion and EPTTCO to develop new cancer treatments based on TAPET delivery system

Second HIV fusion inhibitor developed at Trimeris given fast track designation

Lundbeck: Annual Report 1998

Ophidian: Q2 1999 highlights

New vitronectin receptor ligands emerge from collaborative research at HMR and Genentech

Neuropeptide Y antagonists specifically claimed for use in cardiovascular disorders

Corvas and Schering-Plough extend HCV agreement

Bayer's new CETP inhibitors described in recently published patent

Tokyo Tanabe discloses new antimuscarinic agents

Onyvax licenses anticancer vaccine from CRCT

Antirotavirus polymers in development at GelTex

Abbott prepares semisynthetic rapamycin analogues with reduced half-lives

ImClone commences second phase III trial of C225

SmithKline Beecham describes new series of CCR5 receptor modulators

Preliminary clinical results reported at ASCO for Tularik microtubule inhibitor

XR-9576: first clinical results indicate efficacy, safety and favorable pharmacokinetics

News from ASCO: Genta's G-3139 is effective in treating various cancer types

Immune Response to collaborate with Univ. of Maryland on chemokine research

ASCO highlights: phase I clinical trial results with oral R-115777 alone and in combination regimen

Introgen Therapeutics and RPR Gencell sign CRADA with NCI

Takeda reports discovery of TAK-779, a potent anti-HIV agent with a novel mechanism

Novartis presents first clinical results for Abl tyrosine kinase inhibitor CGP-57148

Novel intranasally administered small peptide shows good efficacy and safety in AIDS-related KS

News from ASCO: clinical pharmacology of Bay-12-9566 assessed in cancer patients

Alcon launches emedastine in U.K. for treatment of seasonal allergic conjunctivitis

ZD-0473 exhibits favorable toxicity profile in phase I studies in solid tumor patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
ATNM-400 radioconjugate shows efficacy in resistant breast cancer
BioWorld Science
Although hormone receptor-positive (HR+) breast cancer accounts for over 70% of cases, 20%-30% of patients still experience relapse despite endocrine therapies...